Furie RA, Bruce IN, Dörner T, et al. - The present study was conducted to explore the dose-response, efficacy, and safety of dapirolizumab pegol (DZP) in patients with systemic lupus erythematosus (SLE). Researchers enrolled adults with moderately to severely active SLE (SLEDAI-2K score ≥ 6 and ≥ 1 BILAG A or ≥ 2 BILAG B domain scores), receiving stable corticosteroid (≤40 mg/day prednisone-equivalent), antimalarial, or immunosuppressant drugs. The data indicate that DZP seemed to be well tolerated, although the primary objective was not met, and individuals showed improvements across multiple clinical and immunological measures of disease activity after 24 weeks relative to placebo. The potential clinical advantage of DZP needs future evaluation.